Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
80 Results for "
SARS-CoV-2 viral replication
" in MedChemExpress (MCE) Product Catalog:
Products (80)
80 Results for "SARS-CoV-2 viral replication" in MCE Product Catalog:
Cat. No.: HY-17036
CAS No.: 173531-58-3
Naphthoquine phosphate is an orally active antimalarial and antiviral agent. Naphthoquine phosphate exhibits ex vivo activity against multidrug-resistant Plasmodium falciparum and Plasmodium vivax, preferentially targeting ring-stage rather than trophozoite-stage parasites. Naphthoquine phosphate inhibits coronavirus (SARS-CoV-2, HCoV-OC43, HCoV-229E) replication by affecting viral entry and post-entry replication. Naphthoquine phosphate is used for research on malaria and Covid-19 .
Cat. No.: HY-162464
MPD2 is a SARS-CoV-2 M Pro PROTAC degrader with an IC50 <1000 nM against SARS-CoV-2 M Pro. MPD2 engages CRBN to mediate ubiquitination and proteasomal degradation of SARS-CoV-2 M Pro, reducing SARS-CoV-2 M Pro protein levels in infected cells. MPD2 inhibits viral replication of various SARS-CoV-2 strains and acts against Nirmatrelvir (HY-138687)-resistant SARS-CoV-2 viruses. MPD2 can be used for the research of COVID-19 and for fighting against drug-resistant viral variants .
Cat. No.: HY-178160
CAS No.: 1581755-42-1
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC50=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC50=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19 .
Cat. No.: HY-175461
CAS No.: 3105041-48-0
AVI-4206 is a selective Mac1 inhibitor with an lC50 of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection .
Cat. No.: HY-109072
CAS No.: 123606-06-4
Target:
Research Areas:
Riamilovir is an oral, broad-spectrum antiviral agent. Riamilovir can directly act on the virus's RNA-dependent RNA polymerase, thereby inhibiting viral replication, reducing viral load, and helping to alleviate the severity of the disease. Riamilovir can be used in research on acute respiratory viral infections caused by novel variants of SARS-CoV-2 .
Cat. No.: HY-131603B
CAS No.: 2736455-56-2
Synonyms: 3TCTP TEA
Research Areas:
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
Cat. No.: HY-N1996R
CAS No.: 23094-71-5
Cat. No.: HY-174350
Target:
Research Areas:
CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .
Cat. No.: HY-162154
CAS No.: 2738323-08-3
SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM .
Cat. No.: HY-173575
Target:
Research Areas:
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC50 value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .
Cat. No.: HY-E70610
Target:
Research Areas:
SARS-CoV-2 main protease is a main protease (Mpro) of SARS-CoV-2, which plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19 .
Cat. No.: HY-161777
Target:
Research Areas:
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM .
Cat. No.: HY-W760546
CAS No.: 3156-41-0
Target:
Research Areas:
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
Cat. No.: HY-164868
CAS No.: 2863607-73-0
SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC50 values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively .
Cat. No.: HY-155014
CAS No.: 1311271-71-2
SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC50 of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .
Cat. No.: HY-156325
CAS No.: 2350285-18-4
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively .
Cat. No.: HY-156337
CAS No.: 2350285-21-9
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively .
Cat. No.: HY-175460
CAS No.: 866036-65-9
SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research .
Cat. No.: HY-145276
CAS No.: 2722634-95-7
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
